Details for Patent: 10,478,500
✉ Email this page to a colleague
Which drugs does patent 10,478,500 protect, and when does it expire?
Patent 10,478,500 protects OXLUMO and is included in one NDA.
This patent has sixty-two patent family members in forty countries.
Summary for Patent: 10,478,500
| Title: | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
| Abstract: | The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. |
| Inventor(s): | Querbes; William (Boston, MA), Fitzgerald; Kevin (Brookline, MA), Bettencourt; Brian (Groton, MA), Liebow; Abigail (Somerville, MA), Erbe; David V. (Arlington, MA) |
| Assignee: | Alnylam Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 15/517,471 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,478,500
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,478,500
| PCT Information | |||
| PCT Filed | October 09, 2015 | PCT Application Number: | PCT/US2015/054881 |
| PCT Publication Date: | April 14, 2016 | PCT Publication Number: | WO2016/057893 |
International Family Members for US Patent 10,478,500
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3204015 | ⤷ Sign Up | 301167 | Netherlands | ⤷ Sign Up |
| European Patent Office | 3204015 | ⤷ Sign Up | PA2022004 | Lithuania | ⤷ Sign Up |
| European Patent Office | 3204015 | ⤷ Sign Up | CA 2022 00011 | Denmark | ⤷ Sign Up |
| European Patent Office | 3204015 | ⤷ Sign Up | 2022C/509 | Belgium | ⤷ Sign Up |
| European Patent Office | 3204015 | ⤷ Sign Up | LUC00252 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 3204015 | ⤷ Sign Up | 122022000018 | Germany | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
